{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ganciclovir+Sodium", "query": { "intervention": "Ganciclovir Sodium" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 133, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ganciclovir+Sodium&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T04:21:45.845Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00000766", "title": "CMV Retinitis Retreatment Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cytomegalovirus Retinitis", "HIV Infections" ], "interventions": [ { "name": "Foscarnet sodium", "type": "DRUG" }, { "name": "Ganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-01", "last_synced_at": "2026-09-24T04:21:45.845Z", "location_count": 9, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000766" }, { "nct_id": "NCT01602614", "title": "Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cytomegalovirus Infections" ], "interventions": [], "intervention_types": [], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "180 Days", "sex": "ALL", "summary": "1 Day to 180 Days" }, "enrollment_count": 18, "start_date": "2013-04", "completion_date": "2019-03", "has_results": true, "last_update_posted_date": "2020-06-02", "last_synced_at": "2026-09-24T04:21:45.845Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01602614" }, { "nct_id": "NCT00002070", "title": "Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cytomegalovirus Retinitis", "HIV Infections" ], "interventions": [ { "name": "Sargramostim", "type": "DRUG" }, { "name": "Ganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Schering-Plough", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-24T04:21:45.845Z", "location_count": 14, "location_summary": "Los Angeles, California • San Francisco, California • Sherman Oaks, California + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Sherman Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002070" }, { "nct_id": "NCT00002251", "title": "A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cytomegalovirus Infections", "HIV Infections" ], "interventions": [ { "name": "Ganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "13 Years to 60 Years" }, "enrollment_count": 20, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-24T04:21:45.845Z", "location_count": 2, "location_summary": "San Francisco, California • Washington D.C., District of Columbia", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002251" }, { "nct_id": "NCT05166577", "title": "Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nasopharyngeal Carcinoma", "EBV-Related Gastric Carcinoma", "EBV-Related Leiomyosarcoma", "EBV Related Carcinoma", "EBV-Related Sarcoma" ], "interventions": [ { "name": "Nanatinostat", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Viracta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-10-08", "completion_date": "2025-01-10", "has_results": true, "last_update_posted_date": "2025-03-12", "last_synced_at": "2026-09-24T04:21:45.845Z", "location_count": 3, "location_summary": "Stanford, California • Aurora, Colorado • Houston, Texas", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05166577" }, { "nct_id": "NCT00002025", "title": "Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cytomegalovirus Infections", "Cytomegalovirus Retinitis", "HIV Infections" ], "interventions": [ { "name": "Ganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": null, "sex": "ALL", "summary": "3 Months and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-24T04:21:45.845Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002025" }, { "nct_id": "NCT04278404", "title": "Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Coronavirus Infection (COVID-19)", "Pulmonary Arterial Hypertension", "Urinary Tract Infections in Children", "Hypertension", "Pain", "Hyperphosphatemia", "Primary Hyperaldosteronism", "Edema", "Hypokalemia", "Heart Failure", "Hemophilia", "Menorrhagia", "Insomnia", "Pneumonia", "Skin Infection", "Arrythmia", "Asthma in Children", "Bronchopulmonary Dysplasia", "Adrenal Insufficiency", "Fibrinolysis; Hemorrhage", "Attention Deficit Hyperactivity Disorder", "Multisystem Inflammatory Syndrome in Children (MIS-C)", "Kawasaki Disease", "Coagulation Disorder", "Down Syndrome" ], "interventions": [ { "name": "The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "0 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "0 Years to 20 Years" }, "enrollment_count": 5000, "start_date": "2020-03-05", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-24T04:21:45.845Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04278404" }, { "nct_id": "NCT00002135", "title": "An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cytomegalovirus Retinitis", "HIV Infections" ], "interventions": [ { "name": "Ganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-24T04:21:45.845Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002135" }, { "nct_id": "NCT02382588", "title": "Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Herpes Zoster Keratitis" ], "interventions": [ { "name": "gancyclovir gel", "type": "DRUG" }, { "name": "Hypromellose gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 8, "start_date": "2013-12-10", "completion_date": "2020-05-11", "has_results": true, "last_update_posted_date": "2021-07-08", "last_synced_at": "2026-09-24T04:21:45.845Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02382588" }, { "nct_id": "NCT00002222", "title": "A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cytomegalovirus Retinitis", "HIV Infections" ], "interventions": [ { "name": "Valganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-24T04:21:45.845Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002222" } ] }